SCHEMBL3973215

SCHEMBL3973215

Cc1ccc(C(N)=O)c(Nc2cc(-c3ccc(F)cc3)nn2-c2ccccc2C)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
JAK2 O60674 2/20 0.41
ADORA1 P30542 1/20 0.40
GRM5 P41594 1/20 0.39
KDM4E B2RXH2 3/20 0.39
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HPGD P15428 1/20 0.37
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36
JAK3 P52333 1/20 0.36
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3974168 0.91 ADORA1 (0.47) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL3975028 0.90 SMN1; SMN2 (0.38) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL4248560 0.87 MAP4K2 (0.47) MAPTALDH1A1LMNAHTTADORA1
SCHEMBL3975648 0.87 HSD17B10 (0.48) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL3974125 0.84 ALDH1A1 (0.46) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL4251798 0.83 MAPT (0.41) MAPTALDH1A1LMNAADORA1GRM5
SCHEMBL3973641 0.81 MAPT (0.40) MAPTALDH1A1LMNAHTTL3MBTL1
SCHEMBL3973588 0.81 MAPK14 (0.56) MAPTLMNAHTTL3MBTL1JAK2
SCHEMBL3979001 0.81 MAPT (0.39) MAPTALDH1A1LMNAHTTADORA1
SCHEMBL3974518 0.81 GRM5 (0.40) MAPTALDH1A1JAK2ADORA1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES BAYER PHARMACEUTICALS CORPORATION (US) 2009-08-20 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-7517878-B2 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARAMCEUTICALS CORPORATION (US) 2009-04-14 US disclosed
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2005-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192294-A1 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes GPR119, GOT2, IAPP MAPT 3713/4885ALDH1A1 943/4885LMNA 3423/4885
US-20090209451-A1 HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES GPR119, GOT2, IAPP MAPT 3713/4885ALDH1A1 943/4885LMNA 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.